Trials / Completed
CompletedNCT02214381
A Prospective, Multicenter, Open-label 12 Week Neoadjuvant Phase II Trial Optimizing Taxane Therapy in Elderly Patients With Low Response
A Prospective, Multicenter, Open-label Comparison of Pre-surgical Myocet/ Cyclophosphamide (MC) q3w Followed by Either MC or Paclitaxel - Depending on Early Response Assessment by Ultrasound or by Toxicity for Elderly Non Frail Primary Breast Cancer Patients With Increased Risk of Relapse.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- Sponsor
- West German Study Group · Academic / Other
- Sex
- Female
- Age
- 70 Years
- Healthy volunteers
- Not accepted
Summary
Comparison of pre-surgical Myocet/ Cyclophosphamide (MC) q3w followed by either MC or Paclitaxel - depending on early response assessment by ultrasound or by toxicity for elderly non frail primary breast cancer patients with increased risk of relapse.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Myocet | |
| DRUG | Cyclophosphamide | |
| DRUG | Paclitaxel |
Timeline
- Start date
- 2014-07-01
- Primary completion
- 2015-10-01
- Completion
- 2025-01-15
- First posted
- 2014-08-12
- Last updated
- 2025-02-27
Locations
2 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT02214381. Inclusion in this directory is not an endorsement.